Introduction
MDR, characterized by a cross-resistance to a number of anticancer agents following exposure to a single drug, is a major problem in the treatment of human cancers. To date, however, only a limited number of genes involved in MDR have been identi®ed, and the biological mechanisms of MDR remain unclear (Baldini, 1997) . For example, the presence of one MDRrelated gene (MDR1) product, P-glycoprotein, correlates with a poor prognosis in some human neoplasms Chan et al., 1990 Chan et al., , 1991 Gottesman and Pastan, 1993) , whereas P-glycoprotein acquisition reduces tumorigenicity and metastatic potential in other cancers (Biedler and Spengler, 1994; Bradley and Ling, 1994; Pinedo and Giaccone, 1995) . These divergent eects of P-glycoprotein may result from dierential interaction with or regulation by other gene products. Thus, further characterization of genes involved in MDR is essential for a comprehensive understanding of the phenomenon.
To identify genes involved in MDR, we searched for genes dierentially expressed between a U-2 OS osteosarcoma cell line and an MDR variant derivative line. Using dierential display analysis, we identi®ed a novel human gene, RB1CC1 (RB1-inducible CoiledCoil 1). Northern blot analysis showed that RB1CC1 expression correlated inversely with that of the MDR1 gene in the parental U-2 OS cells and several MDR variants ( Figure 1a ). Taken together with the ®ndings that RB1CC1 expression was up-regulated and maintained when these cells were growing against anticancer agent (Figure 2) , RB1CC1 repression at the static state may correlate with its less aggressive character in cells with MDR1.
The RB1CC1 cDNA (GenBank accession #AB059622) spans 6.6-kb and contains an open reading frame of 4782 nucleotides, encoding a putative 1594 amino-acid protein with a molecular mass of 180 kDa (Figure 1c ). Homology searches in public databases identi®ed an uncharacterized cDNA, KIAA0203 (D86958) (Nagase et al., 1996) , which was nearly identical to RB1CC1, with the exception of several alterations and nucleotide additions. The putative RB1CC1 protein contains a consensus nuclear localization signal (KPRK), a leucine-zipper motif, and a coiled-coil structure (Figure 1b) , suggesting that RB1CC1 may function as a DNA-binding transcription factor. Consistently, Western blot analysis and immunocytochemical staining demonstrated nuclear localization of the RB1CC1 protein (Figure 1c) .
To investigate the potential role of RB1CC1 in MDR, we compared RB1CC1 expression levels in Oncogene (2002) response to doxorubicin treatment between parental U-2 OS cells, an MDR variant cell line (U-2 OS/DX580) and U-2 OS cells transfected with the MDR1 gene (U-2/DOXO35) (Figure 2a,b) . In parental U-2 OS and transfection control (U-2/Neo8) cells, doxorubicin quickly down-regulated RB1CC1 expression and induced cell death. In contrast, doxorubicin treatment did not negatively aect RB1CC1 expression levels, cell survival or cell proliferation in MDR variant cells, and RB1CC1 expression increased and maintained in cells with MDR1. Interestingly, RB1CC1 expression also correlated well with that of RB1 in these cell lines, and both gene-expressions were maintained when these cells were growing (Figure 2a, b) .
To further explore the association between RB1CC1 and RB1 expression, we examined expression of both genes in ®ve MDR variants of U-2 OS human osteosarcoma cells and 23 human neoplastic cell lines (10 osteosarcomas, four lung cancers, six breast cancers and three hematopoietic neoplasms). RB1CC1 expression correlated strongly with that of RB1 (Figures 2b and 3a) in all cell lines examined. Northern blot analysis of non-neoplastic tissues revealed a similar correlation between RB1CC1 and RB1 expression (a) Northern blot analysis for human RB1CC1 and MDR1. RB1CC1 was identi®ed through dierential display analysis and subsequent semi-quantitative RT ± PCR. RB1CC1 mRNA levels decreased without doxorubicin treatment in MDR variant osteosarcoma cells. Parental U-2 OS human osteosarcoma cells, MDR variant (U-2 OS/DX580), control transfectants (U-2/Neo8, U2/Neo26), and MDR1 transfectants (U-2/MDR117.1, U-2/MDR117.2, U-2/DOXO23 and U-2/DOXO35) were cultured as previously reported (Scotlandi et al., 1996 (Scotlandi et al., , 1999 . Dierential display was performed between U-2 OS and U-2 OS/ DX580 as previously described (Chano et al., 2000) . Northern blot analysis was performed using a speci®c probe (HCC1) spanning nt 4190 ± 4654 of RB1CC1 (GenBank accession #AB059622). The MDR1 probe corresponded to nt 834 ± 1119 of MDR1 (M14758). Probes were labeled with a-32 P dCTP by random priming then hybridized to ®lters under standard conditions. GAPDH was used as a standard for expression. (b) Primary structure of human RB1CC1. RB1CC1 cDNA (AB059622) is 6.6 kb in length and encodes an open reading frame of 4.8 kb. The amino acid sequence contained a pat4 consensus nuclear localization signal at codons 566 ± 569 (open box), a leucine-zipper motif at codons 1371 ± 1392 (double-underlined), and a coiled-coil structure at codons 863 ± 1484 (underlined) . Dierences between the RB1CC1 and KIAA0203 sequences (GenBank accession #D86958) are indicated by black dots. The entire coding region of RB1CC1 was cloned using a single primer pair, CC1S2 (5'-TCA GAG GGT GAG GTA TAA GC-3') and CC1AS2 (5'-TGA GCA CTG CAG GAC AAA TCA-3'). To identify the 5'-and 3'-cDNA sequences, RACE (rapid ampli®cation of cDNA ends) technique was carried out using a RACE kit (Roche). DNA and deduced protein sequences were analysed using DNAsis version 3.2 sequence analysis software (Hitachi Software Engineering, Tokyo, Japan) and PSORT II (http:// www.yk.rim.or.jp/*aisoai/molbio-j.html). (c) Nuclear localization of RB1CC1. Western blot analysis demonstrated *180 kDa RB1CC1 protein in the nuclear fraction. Immunocytochemical staining showed RB1CC1 protein localization (black-stained dots) in the nuclei of U-2 OS cells. Three rabbit polyclonal antibodies were generated against synthetic peptides corresponding to amino acid residues 642 ± 658 (RBICC-642), 744 ± 757 (RBICC-744), and 1104 ± 1118 (RBICC-1104) of human RB1CC1 protein, with an additional amino-terminal cysteine. For immunoblotting and immunocytochemistry, antisera were diluted 1:2000 ± 8000 (Figure 3b ). In addition, exogenous expression of RB1CC1 in K562 and Jurkat cells produced a marked increase in RB1 expression levels (Figure 4a ). MDR1 expression was not detected in those cells, however (data not shown). In the luciferase assay on the transcriptional activity of RB1 promoter, RB1CC1 induction stimulated the RB1 promoter (Figure 4b) . Thus, RB1CC1 introduction up-regulated RB1 expression via the stimulating activity of RB1 promoter.
Taken together, the amino acid sequence features of RB1CC1, its nuclear localization and its expression patterns suggest that RB1CC1 may be a transcription factor that enhances RB1 expression, either directly or indirectly through molecular intermediates. To our knowledge, no transcription factors have been identi®ed that directly regulate RB1 expression, although analyses of human and mouse RB1 promoter sequences indicate that constitutive transcription factors such as Sp1 and ATF may be involved (T'ang et al., 1989; Zacksenhaus et al., 1993) . About 80% of human cancers are associated with molecules in the RB1 pathway, and disregulation of RB1 plays an important role in many human cancers (Kaelin, 1999; Kamb, 1995; Taya, 1997) . Further studies on RB1CC1 will shed light on the regulatory mechanism of the RB1 pathway. Sequential expression of RB1CC1, RB1 and MDR1 under the anticancer agent. In U-2 OS cells, expression of both RB1CC1 and RB1 was barely detectable at 24 ± 48 h following addition of doxorubicin, while their expression levels were maintained in U-2 OS/DX580 cells. Expression patterns were similar between control transfectant (U-2/Neo8) and MDR1-transfected cells (U-2/ DOXO35). Northern blot analysis was performed using RNA extracted at 0, 24, 48, 72, and 120 h following addition of doxorubicin. The HRB1 probe corresponds to nt 336 ± 675 of human RB1 mRNA (GenBank accession #NM_000321) a b Figure 3 Correlation between RB1CC1 and RB1 expression. (a) Semi-quantitative RT ± PCR for RB1CC1 and RB1 in various cancer cell lines. RB1CC1 expression was closely related with RB1 expression in hematopoietic and breast cancer cell lines (the data of only six cell lines were represented in this Figure) . This correlation was also observed in osteosarcoma and lung cancer cell lines (all data not shown). SARG, IOR/OS9, 10, 14, 15, 18 and MOS cell lines were obtained from surgical specimens of high-grade human osteosarcomas (Ferracini et al., 1995) . Saos-2, HOS, MCF-7, T-47D, BT-20, SK-BR3, ZR75-1, MDA-MB-231, Daudi, Jurkat and K562 cell lines were purchased from American Type Culture Collection (Rockvill, MD, USA). LK2, QG56, EBC1 and SBC2 were kindly provided by Dr Tatsuhiko Narita (Laboratory of Experimental Pathology, Aichi Cancer Research Institute, Nagoya, Japan). RT ± PCR was performed by ampli®cation of 22 ± 30 cycles using 2 mg total RNA from each cell line. Oligonucleotide primers corresponding to RB1 were synthesized based on previously reported sequences (Sauerbrey et al., 1996) . Primers used for RB1CC1 were: CC1S, 5'-CCA GGA GCA AGA CAG AGA AC-3' and CC1AS, 5'-CGA GCT CGA TCT TCA GAA AG-3'. b2-microglobin (b2-MG) was used as a standard for expression. (b) Northern blot analysis of RB1CC1 and RB1 in various human tissues. 6.6-kb RB1CC1 transcripts are abundantly expressed in heart and skeletal muscle, and weakly expressed in colon, intestine, lung and leukocytes. The expression pattern of RB1 is almost identical to that of RB1CC1. Northern blots were performed using human MTN TM Blots (Clontech), containing 1mg poly(A)RNA per lane TM -Uni vector (Invitrogen). K562 and Jurkat human leukemic cell lines, which show low levels of endogenous RB1CC1 expression, were transformed with pCR-RBICC or pCR-lacZ, a control plasmid containing the lacZ gene, by electroporation (Potter et al., 1984) . Stable RB1CC1 transformants were selected using 800 mg/ml G418 (GIBCO). (b) Eect of RB1CC1 induction on the transcriptional activity of the RB1 promoter. RB1CC1 induction up-regulated the luciferase activity by stimulating pGV-RbPro vector, in which RB1 promoter governed the ®re¯y luciferase expression. The 2-kb RB1 promoter region was ampli®ed using a primer pair, Bgl.RbPro-S (5'-GAA GAT CTT TGA AAT TCC TCC TGC ACC A-3') and Hind.RbPro-AS (5'-CCC AAG CTT AGC CAG CGA GCT GTG GAG-3'), cloned into PicaGene Basic Vector 2 (ToyoInk, Tokyo), and then pGV-RbPro was constructed. The pGV-RbPro was co-transfected with pRL-SV40 (ToyoInk, Tokyo), which encodes the SeaPansy luciferase gene for the internal control, into the transformed K562 cells, by LIPOFECTAMINE PLUS TM reagent (GIBCO). After 48 h of the co-transfection, luciferase activities were assayed by the dual luciferase assay system (ToyoInk). The vertical axis shows the ratio of ®re¯y luciferase activity to SeaPansy luciferase activity (n=4; *P=0.0003)
